Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Lyashchenko

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Nuclear Medicine Communications|October 9, 2013
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancerVolkan Beylergil, Patrick G Morris, Peter M Smith-Jones, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic CancerChristian Lohrmann, Eileen M O'Reilly, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using <sup>89</sup>Zr-Trastuzumab PET: A Pilot StudyMelissa A Lumish, Steven B Maron, Viktoriya Paroder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I StudyShakeel Modak, Pat Zanzonico, Milan Grkovski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2016
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CTGary A Ulaner, David M Hyman, Dara S Ross, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2017
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for <sup>89</sup>Zr-Trastuzumab in Patients with Esophagogastric CancerJoseph A O'Donoghue, Jason S Lewis, Neeta Pandit-Taskar, et al.
EJNMMI Radiopharmacy and Chemistry|July 19, 2022
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticalsAruna Korde, Renata Mikolajczak, Petra Kolenc, et al.
EJNMMI Research|October 8, 2024
[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancerPhilipp Backhaus, Keith S Pentlow, Alan L Ho, et al.
The Lancet. Oncology|June 20, 2018
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trialMark M Souweidane, Kim Kramer, Neeta Pandit-Taskar, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Nuclear Medicine Communications|October 9, 2013
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancerVolkan Beylergil, Patrick G Morris, Peter M Smith-Jones, et al.
Radiology|June 10, 2020
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted <sup>89</sup>Zr-Pertuzumab PET/CTGary A Ulaner, Jorge A Carrasquillo, Christopher C Riedl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic CancerChristian Lohrmann, Eileen M O'Reilly, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using <sup>89</sup>Zr-Trastuzumab PET: A Pilot StudyMelissa A Lumish, Steven B Maron, Viktoriya Paroder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I StudyShakeel Modak, Pat Zanzonico, Milan Grkovski, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2016
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CTGary A Ulaner, David M Hyman, Dara S Ross, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2017
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for <sup>89</sup>Zr-Trastuzumab in Patients with Esophagogastric CancerJoseph A O'Donoghue, Jason S Lewis, Neeta Pandit-Taskar, et al.
EJNMMI Radiopharmacy and Chemistry|July 19, 2022
Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticalsAruna Korde, Renata Mikolajczak, Petra Kolenc, et al.
EJNMMI Research|October 8, 2024
[<sup>18</sup>F]TFB PET/CT misses intense [<sup>124</sup>I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancerPhilipp Backhaus, Keith S Pentlow, Alan L Ho, et al.
The Lancet. Oncology|June 20, 2018
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trialMark M Souweidane, Kim Kramer, Neeta Pandit-Taskar, et al.
Pageof 8